Vitalgen
Latest round
- Series B
Last raised
- Apr 2025
Total raised
- Undisclosed
Investors
- 12
About Vitalgen
, trading as Vitalgen, specializes in pioneering gene therapy solutions. Vitalgen develops advanced gene delivery and editing technologies aimed at treating various genetic and neurodegenerative disorders. Its core products include ViVec® AAV vector technology, ViLNP® lipid nanoparticle technology, and ViCas® CRISPR gene editing technology. The company is actively advancing multiple products into clinical research, targeting global markets for diseases such as AADC deficiency and amyotrophic lateral sclerosis (ALS). The company generates revenue from partnerships and collaborations with biopharmaceutical companies, alongside direct sales of its gene therapy products. The company plans to launch additional innovative gene therapies and aims to penetrate broader geographic regions beyond China, enhancing its global reach in the gene therapy sector.
Who invested in Vitalgen
12 investors across 6 rounds
See all investors in Vitalgen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Apr 20, 2025
Amount
Undisclosed
Investors
Series B
Aug 13, 2023
Amount
Undisclosed
Investors
Series B
Mar 2, 2023
Amount
Undisclosed
Investors
Series A
Oct 14, 2021
Amount
Undisclosed
Investors
Series A
May 24, 2021
Amount
Undisclosed
Investors
Angel
Jul 15, 2020
Amount
Undisclosed
Investors
Questions about Vitalgen
Who invested in Vitalgen?
Vitalgen has 12 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vitalgen raised?
Vitalgen has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Vitalgen last raise money?
Vitalgen's most recent round on record is a Series B, in Apr 2025.
What does Vitalgen do?
, trading as Vitalgen, specializes in pioneering gene therapy solutions.
Where is Vitalgen headquartered?
Vitalgen is headquartered in Shanghai, China.
Which VCs invest in companies like Vitalgen?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Vitalgen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Vitalgen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.